2025-08-05T21:02:46.716854+0800 INFO SYS-Warmup function started
2025-08-05T21:02:46.716951+0800 INFO CONFIG-Config path: configs/main.json
2025-08-05T21:02:46.717019+0800 INFO CONFIG-Config: {'chat_config': {'chat_model': 'Qwen/Qwen3-8B', 'lora': False, 'chat_model_type': 'chat', 'chat_model_inference_engine': 'openai', 'chat_system_message': 'You are a helpful assistant.', 'chat_endpoint': 'https://api.siliconflow.cn/v1/chat/completions', 'chat_parameters': {'temperature': 0.6, 'max_tokens': 1024}, 'chat_request_sleep': {'sleep_time': 2, 'sleep_every_count': 10}, 'chat_max_new_token': 1000, 'chat_request_timeout': 1000, 'chat_vllm_endpoint': 'http://0.0.0.0:8000'}, 'emb_config': {'emb_model_name': 'Qwen/Qwen3-Embedding-4B', 'request_endpoint': 'https://api.siliconflow.cn/v1/embeddings', 'emb_size': 2560, 'embedding_timeout': 600}, 'env_config': {'trading_symbols': ['JNJ'], 'warmup_start_time': '2020-07-02', 'warmup_end_time': '2020-07-10', 'test_start_time': '2020-10-01', 'test_end_time': '2021-05-06', 'momentum_window_size': 3, 'env_data_path': {'JNJ': 'data/jnj.json'}}, 'portfolio_config': {'trading_symbols': ['JNJ'], 'type': 'single-asset', 'look_back_window_size': 3}, 'agent_config': {'agent_name': 'agent', 'trading_symbols': ['JNJ'], 'character_string': {'JNJ': "You accumulate a lot of information about Johnson & Johnson (JNJ) in the following sectors so you are especially good at trading them: (1) Pharmaceuticals Sector: This is the largest segment of Johnson & Johnson, involving the research, development, and sale of pharmaceutical products across various therapeutic areas such as immunology, oncology, neurology, and infectious diseases. (2) Medical Devices Sector: JNJ is a significant player in the medical devices sector, providing a wide range of products used in orthopedics, surgery, cardiovascular, diabetes care, and other fields. (3) Consumer Health Sector: This sector includes a broad array of over-the-counter (OTC) products, skin care products, and baby care products, among other consumer health items. You are an investment expert of Johnson & Johnson (JNJ). You learned the following knowledge about Johnson & Johnson (JNJ) based on your professional experience. Johnson & Johnson (JNJ) demonstrated robust financial performance in 2019, generating revenues of $82.1 billion, up 0.6% from the previous year, driven by strong sales in its pharmaceuticals and medical devices segments. The company's net earnings for the year stood at $15.1 billion, reflecting a solid operational performance and strategic management of its diversified healthcare portfolio. JNJ's stock performed well in 2019, buoyed by consistent earnings growth and a reputation for stability in the healthcare sector. In 2020, JNJ faced unprecedented challenges due to the COVID-19 pandemic, impacting its medical devices segment due to reduced elective surgeries. However, its pharmaceuticals and consumer health divisions saw increased demand, particularly for products related to immune health and hygiene. By the end of the third quarter of 2020, JNJ's stock had shown resilience, recovering from a dip in March, driven by positive news regarding its progress on a COVID-19 vaccine candidate and stable financial performance despite global economic uncertainties. At the beginning of the fourth quarter of 2020, professional analysts were optimistic about Johnson & Johnson (JNJ) for the rest of the year and into 2021. They expected continued resilience in JNJ's pharmaceutical and consumer health segments, which could offset challenges faced by the medical devices division due to the pandemic. For 2021, analysts were particularly positive about the potential approval and distribution of JNJ’s COVID-19 vaccine, which could significantly boost the company’s profile and financial performance, alongside a recovery in elective medical procedures as global conditions improve."}, 'top_k': 5, 'memory_db_config': {'memory_db_endpoint': 'http://localhost:6333', 'memory_importance_upper_bound': 100.0, 'memory_importance_score_update_step': 18.0, 'trading_symbols': ['JNJ'], 'short': {'db_name': 'short', 'importance_init_val': 50.0, 'decay_recency_factor': 3.0, 'decay_importance_factor': 0.92, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'jump_upper_threshold': 55.0}, 'mid': {'db_name': 'mid', 'importance_init_val': 60.0, 'decay_recency_factor': 90.0, 'decay_importance_factor': 0.96, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'jump_lower_threshold': 55.0, 'jump_upper_threshold': 85.0}, 'long': {'db_name': 'long', 'importance_init_val': 90.0, 'decay_recency_factor': 365.0, 'decay_importance_factor': 0.96, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'jump_lower_threshold': 85.0}, 'reflection': {'db_name': 'reflection', 'importance_init_val': 80.0, 'decay_recency_factor': 365.0, 'decay_importance_factor': 0.98, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'similarity_threshold': 0.95}}}, 'meta_config': {'run_name': 'exp', 'momentum_window_size': 3, 'warmup_checkpoint_save_path': 'results/exp/qwen3-8b-siliconflow/JNJ/warmup_checkpoint', 'warmup_output_save_path': 'results/exp/qwen3-8b-siliconflow/JNJ/warmup_output', 'test_checkpoint_save_path': 'results/exp/qwen3-8b-siliconflow/JNJ/test_checkpoint', 'test_output_save_path': 'results/exp/qwen3-8b-siliconflow/JNJ/test_output', 'result_save_path': 'results/exp/qwen3-8b-siliconflow/JNJ/final_result', 'log_save_path': 'results/exp/qwen3-8b-siliconflow/JNJ/log'}}
2025-08-05T21:02:46.717093+0800 INFO ENV-Creating MarketEnvironment with params: env_data_pkl {'JNJ': 'data/jnj.json'}, start_date 2020-07-02, end_date 2020-07-10, symbol ['JNJ']
2025-08-05T21:02:46.718596+0800 INFO ENV-Final date series (intersection): [datetime.date(2020, 7, 2), datetime.date(2020, 7, 6), datetime.date(2020, 7, 7), datetime.date(2020, 7, 8), datetime.date(2020, 7, 9), datetime.date(2020, 7, 10)]
2025-08-05T21:02:46.718629+0800 INFO ENV-Simulation-Length: 6
2025-08-05T21:02:46.718661+0800 INFO SYS-Initializing FinMemAgent
2025-08-05T21:02:46.718727+0800 INFO SYS-Initializing MemoryDB
2025-08-05T21:02:46.811376+0800 INFO SYS-Portfolio type: single-asset
2025-08-05T21:02:46.811951+0800 INFO **************************************************
2025-08-05T21:02:46.811999+0800 INFO ENV- current date: 2020-07-02, future date: 2020-07-06
2025-08-05T21:02:46.812065+0800 INFO ENV-Current price: {'JNJ': 126.29952239990234}, future price diff: {'JNJ': -0.014258202279512232}
2025-08-05T21:02:46.812105+0800 INFO ENV-Current news: {'JNJ': ["inHEART has raised EUR 3.7 million to enhance its cloud-based medical image analysis solution for cardiac arrhythmias, aiming to accelerate commercial development in Europe and enter the US market. The technology, which creates a 3D digital twin of the patient's heart, has been used on over 2000 patients in 40 centers globally, improving procedure efficiency and reducing recurrence rates. The funding round was led by Elaia, a VC firm known for backing tech disruptors, indicating strong investor confidence. inHEART's solution addresses a significant clinical need in the EUR 5 billion cardiac electrophysiology market, which includes major players like Johnson & Johnson. The company's technology, backed by French academic excellence, has received positive clinical feedback and is poised for further advancements with AI integration. (Sentiment: positive)", 'The Global Organic Cosmetics Market is projected to grow significantly through 2025, driven by increasing consumer awareness of chemical impacts and a preference for eco-friendly products. Supportive government policies and rising health and hygiene spending, particularly among working women, are key growth drivers. However, challenges such as the shorter shelf life of organic products and the impact of COVID-19 on consumer spending and supply chains may hinder growth. North America and Europe are expected to dominate the market due to health-conscious populations and the presence of major players. For Johnson & Johnson (JNJ), this market presents opportunities for expansion and innovation in organic product lines, aligning with consumer trends and regulatory support. (Sentiment: positive)']}
2025-08-05T21:02:46.812139+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-05T21:02:46.812165+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-05T21:02:46.812189+0800 INFO ENV-Current momentum: {'JNJ': None}
2025-08-05T21:02:46.812213+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-05T21:02:46.812248+0800 INFO ENV-new info from env
2025-08-05T21:02:46.812275+0800 INFO ENV-date: 2020-07-02
2025-08-05T21:02:46.812300+0800 INFO ENV-price: {'JNJ': 126.29952239990234}
2025-08-05T21:02:46.812326+0800 INFO ENV-news-JNJ-0: inHEART has raised EUR 3.7 million to enhance its cloud-based medical image analysis solution for cardiac arrhythmias, aiming to accelerate commercial development in Europe and enter the US market. The technology, which creates a 3D digital twin of the patient's heart, has been used on over 2000 patients in 40 centers globally, improving procedure efficiency and reducing recurrence rates. The funding round was led by Elaia, a VC firm known for backing tech disruptors, indicating strong investor confidence. inHEART's solution addresses a significant clinical need in the EUR 5 billion cardiac electrophysiology market, which includes major players like Johnson & Johnson. The company's technology, backed by French academic excellence, has received positive clinical feedback and is poised for further advancements with AI integration. (Sentiment: positive)
2025-08-05T21:02:46.812382+0800 INFO --------------------------------------------------
2025-08-05T21:02:46.812407+0800 INFO ENV-news-JNJ-1: The Global Organic Cosmetics Market is projected to grow significantly through 2025, driven by increasing consumer awareness of chemical impacts and a preference for eco-friendly products. Supportive government policies and rising health and hygiene spending, particularly among working women, are key growth drivers. However, challenges such as the shorter shelf life of organic products and the impact of COVID-19 on consumer spending and supply chains may hinder growth. North America and Europe are expected to dominate the market due to health-conscious populations and the presence of major players. For Johnson & Johnson (JNJ), this market presents opportunities for expansion and innovation in organic product lines, aligning with consumer trends and regulatory support. (Sentiment: positive)
2025-08-05T21:02:46.812433+0800 INFO --------------------------------------------------
2025-08-05T21:02:46.812458+0800 INFO ENV-momentum: {'JNJ': None}
2025-08-05T21:02:46.812482+0800 INFO ENV-symbol: ['JNJ']
2025-08-05T21:02:46.812506+0800 INFO ==================================================
2025-08-05T21:02:46.812536+0800 INFO AGENT-Step, date: 2020-07-02, run mode: RunMode.WARMUP, task type: TaskType.SingleAsset
2025-08-05T21:02:46.812560+0800 INFO AGENT-Handling new information
2025-08-05T21:02:47.273729+0800 INFO AGENT-Querying memories
2025-08-05T21:02:48.809065+0800 INFO ##################################################
2025-08-05T21:02:48.809357+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-05T21:02:48.809438+0800 INFO AGENT-Short Memory: 2, The Global Organic Cosmetics Market is projected to grow significantly through 2025, driven by increasing consumer awareness of chemical impacts and a preference for eco-friendly products. Supportive government policies and rising health and hygiene spending, particularly among working women, are key growth drivers. However, challenges such as the shorter shelf life of organic products and the impact of COVID-19 on consumer spending and supply chains may hinder growth. North America and Europe are expected to dominate the market due to health-conscious populations and the presence of major players. For Johnson & Johnson (JNJ), this market presents opportunities for expansion and innovation in organic product lines, aligning with consumer trends and regulatory support. (Sentiment: positive)
2025-08-05T21:02:48.809517+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-05T21:02:48.809594+0800 INFO AGENT-Short Memory: 1, inHEART has raised EUR 3.7 million to enhance its cloud-based medical image analysis solution for cardiac arrhythmias, aiming to accelerate commercial development in Europe and enter the US market. The technology, which creates a 3D digital twin of the patient's heart, has been used on over 2000 patients in 40 centers globally, improving procedure efficiency and reducing recurrence rates. The funding round was led by Elaia, a VC firm known for backing tech disruptors, indicating strong investor confidence. inHEART's solution addresses a significant clinical need in the EUR 5 billion cardiac electrophysiology market, which includes major players like Johnson & Johnson. The company's technology, backed by French academic excellence, has received positive clinical feedback and is poised for further advancements with AI integration. (Sentiment: positive)
2025-08-05T21:02:48.809651+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-05T21:02:48.809713+0800 INFO AGENT-Single asset task
